FOCUS PHARMA
ActiveSummary
FOCUS PHARMA has been active since 2012 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€91,912) and a net result of -€20,562. Equity is shrinking by about 63% per year across the filed financial years. Its solvency ranks better than 5% of 9,701 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
History
Acts, filings and financial milestones
06-11
Gazette deed
Reappointments: Peter Van Ruyskensvelde (managing director) and Maria Lemmens (director)4 facts ▸
- General meeting, 29-05-2024
- Director reappointment, Peter Van Ruyskensvelde (managing director)
- Director reappointment, Peter Van Ruyskensvelde (director)
- Director reappointment, Maria Lemmens (director)
About the unread acts
Of the 5 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 4 have not been read yet: what they contain is neither established nor disproved here.